- Home
- MED vs CLLS Comparison
MED vs CLLS Comparison
Compare MED & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MED
- CLLS
- Stock Information
- Founded
- MED 1980
- CLLS 1999
- Country
- MED United States
- CLLS France
- Employees
- MED N/A
- CLLS N/A
- Industry
- MED Packaged Foods
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- MED Consumer Staples
- CLLS Health Care
- Exchange
- MED Nasdaq
- CLLS Nasdaq
- Market Cap
- MED 144.4M
- CLLS 144.4M
- IPO Year
- MED N/A
- CLLS 2007
- Fundamental
- Price
- MED $12.93
- CLLS $1.53
- Analyst Decision
- MED Hold
- CLLS Buy
- Analyst Count
- MED 1
- CLLS 3
- Target Price
- MED $16.50
- CLLS $7.00
- AVG Volume (30 Days)
- MED 219.7K
- CLLS 84.6K
- Earning Date
- MED 04-28-2025
- CLLS 05-27-2025
- Dividend Yield
- MED N/A
- CLLS N/A
- EPS Growth
- MED N/A
- CLLS N/A
- EPS
- MED N/A
- CLLS N/A
- Revenue
- MED $543,452,000.00
- CLLS $49,217,000.00
- Revenue This Year
- MED N/A
- CLLS $48.52
- Revenue Next Year
- MED N/A
- CLLS $5.17
- P/E Ratio
- MED N/A
- CLLS N/A
- Revenue Growth
- MED N/A
- CLLS 435.38
- 52 Week Low
- MED $11.57
- CLLS $1.10
- 52 Week High
- MED $27.16
- CLLS $3.32
- Technical
- Relative Strength Index (RSI)
- MED 49.24
- CLLS 56.17
- Support Level
- MED $12.61
- CLLS $1.54
- Resistance Level
- MED $13.27
- CLLS $1.65
- Average True Range (ATR)
- MED 0.50
- CLLS 0.08
- MACD
- MED 0.13
- CLLS -0.00
- Stochastic Oscillator
- MED 70.21
- CLLS 58.62
About MED MEDIFAST INC
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. OPTAVIA provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. Medifast remains committed to its mission of offering Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.